Industry news

Germany, U.S. in hot pursuit of "messenger" drug molecules

Ludwig Burger and Ben Hirschler / Reuters

A molecule that carries the recipe for making drugs inside body cells is exciting scientists and investors alike, attracting hundreds of millions of dollars in a scramble for the next promising area of biotechnology.

China’s drug innovation – Is it at a tipping point?

Shannon Ellis / BioWorld

Chinese innovation has long been a fraught topic: Does China have it? If so, what is it? When will it be globally relevant? And, if you want to really get people going just ask if China can innovate at all. Some are optimistic that China is on the right path to become a true global innovation participant. McKinsey & Co. decided it was time to tackle this hot topic in its own fashion with a survey of industry leaders who have one foot in China and the other abroad.

13 November 2015

Epic Sciences Partners with University of Pennsylvania's Abramson Cancer Center on Cancer Therapy Discoveries through Liquid Biopsy

Epic Sciences, Inc. announced today a collaboration with the Abramson Cancer Center of the University of Pennsylvania (Penn) on multiple studies to explore biomarkers, identified by analysis of circulating tumor cells (CTCs) at a single cell resolution, that are predictive of response to personalized cancer therapeutics.

Science? Management? Indication? Why VCs might say no to your Deal

Randy Osborne / Life Sciences Connect

Science or technology that fails to measure up and weak leadership make for sure-fire deal-killers in the venture capital (VC) world, but there’s more to it, said Jay Lichter, managing partner with Avalon Ventures in San Diego.

Pre-approval access: Walking a moral, ethical financial tightrope

Jennifer Boggs / BioWorld

The needs of the many outweighing the needs of the one might seem the acme of logic, at least for a Vulcan. For humans, it's not so simple, and it's only one of several thorny problems industry, government and society must resolve to establish clear guidance to provide dying patients with compassionate use access to experimental drugs.

Stanford engineers develop touch-free ultrasound device for tumor detection

Emily Wasserman / FierceMedicalDevices

As scientists search for lighter, low-cost alternatives to traditional imaging tools such as MRI or CT scans, engineers at Stanford University are developing a device that uses microwaves and ultrasound to pinpoint targets without touch, potentially improving tumor detection.

What's pharma got to say about pricing? PhRMA has some ideas

Beth Snyder Bulik / FiercePharmaMarketing

As pricing issues continue to drag on pharma's reputation, the industry is finally pushing back hard, starting with the industry's lead trade association.

12 November 2015

Clearside Biomedical, Inc. Announces Fifth Patent Issued in the U.S. Related To Proprietary Microneedle Drug Delivery Methods and Devices

Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced the U.S. Patent and Trademark Office (USPTO) granted U.S. Patent Application No. 14/523,243 as U.S. Patent No. 9,180,047 in a patent titled, "Apparatus and Methods for Ocular Injection."

B2C, healthcare industries driving record year for M&A value

PitchBook Blog

4Q 2015 M&A Report takes a look into aggregate M&A activity across North America and Europe, spotlighting a few key industries and analyzing sponsor-backed trends. As it turns out, total M&A value is on track for an all-time record, spurred by massive numbers in the B2C and healthcare sectors. 

12 November 2015

Neothetics Reports Third Quarter 2015 Financial Results

Neothetics, Inc.  (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported financial results and business progress for the third quarter 2015.